Biodesix to Participate in William Blair’s 43rd Annual Growth Stock ...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 4, 2023

Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid • NBLSA and Blueprint Prep Join Forces to Increase Diversity in the Legal Field • Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception • Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers • CAMS Wins Ragan CSR, ESG and Diversity Awards • Riddle & Brantley Partners with Groundbreaking Nonprofit to Combat the Growing Mental Health Crisis Facing Today's Youth • Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call • Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio • Global Clean Energy Reports Largest Camelina Acreage Worldwide • Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team • BioTek reMEDys Calls for Heightened Communication Around Health Literacy Month • MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX • Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs • HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation' • THE COMMUNITY SPIRIT VODKA JOINS FORCES WITH ONE GRAND BOOKS TO CELEBRATE LGBTQ+ HISTORY MONTH THROUGH LITERATURE • UCB presents late-breaking posters at Child Neurology Society Meeting • Qwoted Launches Free Networking Tools for PR Industry • Dr. Toba N. Niazi Appointed Chief of the Section of Neurosurgery and Co-Director of Nicklaus Children's Brain Institute • ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives • Enjoy Prime Big Deals from Jackery: Up to 40% OFF Fan Favorites From Oct. 1 Through Oct. 11, And $50,000 Worth of Giveaways

Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference

BOULDER, Colo. , May 31 /Businesswire/ - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.

William Blair’s 43rd Annual Growth Stock Conference

Presentation Date: Wednesday, June 7, 2023

Presentation Time: 4:40 PM CT

Location: Loews Chicago Hotel, Chicago, IL

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix's website at Biodesix.com.

About Biodesix

Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.